Combination Therapy with Chemotherapy and VDAs
作者： Giulia Taraboletti , Katiuscia Bonezzi , Raffaella Giavazzi
DOI: 10.1007/978-1-4419-6609-4_4
关键词: Disease Response 、 Metronomic Chemotherapy 、 Combination therapy 、 Tumor vasculature 、 Tumor microenvironment 、 Cytotoxic drug 、 Pharmacology 、 Drug 、 Medicine 、 Chemotherapy
摘要: A growing body of preclinical and clinical evidence substantiates the feasibility combining vascular disrupting agents (VDAs) conventional anticancer therapies. The enhanced disease response to this combination is attributable respective activity VDAs on tumor vasculature cytotoxic drug proliferating cells. However, nature mode action likely cause pathophysiological modifications in microenvironment that can influence delivery with which combined. full understanding VDAs, together pharmacological interactions drugs, will expedite approaches aiming maximize antitumor effects therapy. This review focuses rationales underpinning small molecule chemotherapy, discussing changes associated VDA implication these for modalities.
springer.com
elsevier.com
sci-hub.st 参考文章(52)
S. D. Shnyder, George Pettit, P. A. Cooper, J. W. Lippert, M. C. Bibby, Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Research. ,vol. 23, pp. 1619- 1623 ,(2003)
George Pettit, D. J. Swaine, P. M. Loadman, K. Grosios, M. C. Bibby, Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Research. ,vol. 20, pp. 229- 233 ,(2000)
Barbara Imberti, Patrizia Borsotti, Raffaella Giavazzi, Giulia Taraboletti, Maura Poli, Michele Martinelli, Gianluca Micheletti, Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Research. ,vol. 63, pp. 1534- 1537 ,(2003)
Jason L. Dearling, R. Barbara Pedley, Uzma A. Qureshi, Sally A. Hill, Ross J. Maxwell, Gillian M. Tozer, Ethaar El-Emir, Katharine J. Lankester, Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down International Journal of Oncology. ,vol. 30, pp. 453- 460 ,(2007) , 10.3892/IJO.30.2.453
Timothy J. Jorgensen, Hui Tian, Ingrid B. J. K. Joseph, Krishna Menon, David Frost, Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth Cancer Chemotherapy and Pharmacology. ,vol. 59, pp. 725- 732 ,(2007) , 10.1007/S00280-006-0326-2
Gillian M. Tozer, Chryso Kanthou, Bruce C. Baguley, Disrupting tumour blood vessels Nature Reviews Cancer. ,vol. 5, pp. 423- 435 ,(2005) , 10.1038/NRC1628
Dietmar W Siemann, Amyn M Rojiani, Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. International Journal of Radiation Oncology Biology Physics. ,vol. 54, pp. 1512- 1517 ,(2002) , 10.1016/S0360-3016(02)03919-6
Dietmar W. Siemann, Emma Mercer, Sharon Lepler, Amyn M. Rojiani, Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy International Journal of Cancer. ,vol. 99, pp. 1- 6 ,(2002) , 10.1002/IJC.10316
M Martinelli, K Bonezzi, E Riccardi, E Kuhn, R Frapolli, M Zucchetti, A J Ryan, G Taraboletti, R Giavazzi, Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel British Journal of Cancer. ,vol. 97, pp. 888- 894 ,(2007) , 10.1038/SJ.BJC.6603969
John W. Lippert, Vascular disrupting agents. Bioorganic & Medicinal Chemistry. ,vol. 15, pp. 605- 615 ,(2007) , 10.1016/J.BMC.2006.10.020